
Hossein Haji Ali Afzali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2489984/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies. International Journal of Technology Assessment in Health Care, 2021, 37, e22.	0.5	4
2	Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. Value in Health, 2021, 24, 755-758.	0.3	3
3	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. Applied Health Economics and Health Policy, 2020, 18, 1-4.	2.1	5
4	Are the benefits of new health services greater than their opportunity costs?. Australian Health Review, 2019, 43, 508-510.	1.1	3
5	Lifetime costs of invasive meningococcal disease: A Markov model approach. Vaccine, 2019, 37, 6885-6893.	3.8	8
6	Structuring a conceptual model for cost-effectiveness analysis of frailty interventions. PLoS ONE, 2019, 14, e0222049.	2.5	11
7	Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine, 2019, 37, 2768-2782.	3.8	121
8	The development of funding recommendations for health technologies at the state level: A South Australian case study. International Journal of Health Planning and Management, 2018, 33, 806-822.	1.7	1
9	Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. Pharmacoeconomics, 2018, 36, 239-252.	3.3	153
10	Model Structuring for Economic Evaluations of New Health Technologies. Pharmacoeconomics, 2018, 36, 1309-1319.	3.3	13
11	Is the Counterweight Program a feasible and acceptable option for structured weight management delivered by practice nurses in Australia? A mixed-methods study. Australian Journal of Primary Health, 2017, 23, 348.	0.9	4
12	A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention. Applied Health Economics and Health Policy, 2017, 15, 635-645.	2.1	10
13	Adolescent values for immunisation programs in Australia: A discrete choice experiment. PLoS ONE, 2017, 12, e0181073.	2.5	21
14	Adolescent confidence in immunisation: Assessing and comparing attitudes of adolescents and adults. Vaccine, 2016, 34, 5595-5603.	3.8	11
15	Should the Lambda (λ) Remain Silent?. Pharmacoeconomics, 2016, 34, 323-329.	3.3	6
16	Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee. Applied Health Economics and Health Policy, 2016, 14, 401-407.	2.1	14
17	Exploring Structural Uncertainty in Model-Based Economic Evaluations. Pharmacoeconomics, 2015, 33, 435-443.	3.3	24
18	Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions. Pharmacoeconomics, 2015, 33, 777-781.	3.3	8

Hossein Haji Ali Afzali

#	ARTICLE	IF	CITATIONS
19	Practice nurse involvement in general practice clinical care: policy and funding issues need resolution. Australian Health Review, 2014, 38, 301.	1.1	18
20	Community, parental and adolescent awareness and knowledge of meningococcal disease. Vaccine, 2014, 32, 2042-2049.	3.8	23
21	Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis. BMC Family Practice, 2014, 15, 10.	2.9	5
22	The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine, 2014, 32, 4791-4798.	3.8	31
23	When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES. Pharmacoeconomics, 2014, 32, 547-558.	3.3	51
24	The Clinical Burden And Predictors of Sequelae Following Invasive Meningococcal Disease In Australian Children. Pediatric Infectious Disease Journal, 2014, 33, 316-318.	2.0	25
25	Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases. Applied Health Economics and Health Policy, 2013, 11, 85-93.	2.1	18
26	A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with TypeÂ2 Diabetes in Australia. Applied Health Economics and Health Policy, 2013, 11, 661-670.	2.1	6
27	Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions. Medical Decision Making, 2013, 33, 325-332.	2.4	31
28	A Critical Review of Model-Based Economic Studies of Depression. Pharmacoeconomics, 2012, 30, 461-482.	3.3	28
29	A proposed model for economic evaluations of major depressive disorder. European Journal of Health Economics, 2012, 13, 501-510.	2.8	16
30	A model-based evaluation of collaborative care in management of patients with type 2 diabetes in Australia: an initial report. Australian Health Review, 2012, 36, 258.	1.1	4
31	Evaluation of collaborative models of care in the management of patients with depression: protocol and progress. Mental Health in Family Medicine, 2012, 9, 91-7.	0.2	1
32	Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions. Pharmacoeconomics, 2011, 29, 823-825.	3.3	16
33	Exploring health professionals' perspectives on factors affecting Iranian hospital efficiency and suggestions for improvement. International Journal of Health Planning and Management, 2011, 26, e17-29.	1.7	6
34	A conceptual framework for selecting the most appropriate variables for measuring hospital efficiency with a focus on Iranian public hospitals. Health Services Management Research, 2009, 22, 81-91.	1.7	21